Free tool
FAERS Monitor: Tecfidera
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 204063 or its brand name (Tecfidera, Dimethyl Fumarate). Reports on generic versions are filed under their own applications.
Reports
122,568
Serious
40,867
33% of reports
Hospitalization
22,929
Death reported
2,171
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- flushing17,125
- nausea8,981
- diarrhoea8,302
- multiple sclerosis relapse8,147
- fatigue6,970
- multiple sclerosis5,766
- vomiting5,659
- memory impairment5,573
- gastric disorder5,551
- abdominal pain upper5,420
- drug ineffective5,238
- pruritus5,080
- headache5,048
- fall5,027
- gait disturbance4,626
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 5 |
| 2012 | 14 |
| 2013 | 14,596 |
| 2014 | 18,283 |
| 2015 | 12,884 |
| 2016 | 13,524 |
| 2017 | 12,338 |
| 2018 | 12,142 |
| 2019 | 10,538 |
| 2020 | 9,477 |
| 2021 | 6,132 |
| 2022 | 5,229 |
| 2023 | 3,259 |
| 2024 | 1,755 |
| 2025 | 1,526 |
| 2026 | 863 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,931,591 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| flushingSignal | 17,125 | 34.6 | 34.0 | 466,296 |
| gastric disorderSignal | 5,551 | 32.9 | 32.0 | 144,204 |
| multiple sclerosisSignal | 5,766 | 23.4 | 22.8 | 108,924 |
| multiple sclerosis relapseSignal | 8,147 | 23.0 | 22.5 | 151,646 |
| memory impairmentSignal | 5,573 | 7.2 | 7.0 | 28,797 |
| abdominal pain upperSignal | 5,420 | 4.6 | 4.5 | 15,075 |
| gait disturbanceSignal | 4,626 | 4.2 | 4.1 | 11,213 |
| fallSignal | 5,027 | 2.6 | 2.5 | 5,022 |
| pruritusSignal | 5,080 | 2.3 | 2.2 | 3,690 |
| diarrhoeaSignal | 8,302 | 2.2 | 2.2 | 5,686 |
| vomitingSignal | 5,659 | 2.1 | 2.0 | 3,199 |
| nausea | 8,981 | 2.0 | 1.9 | 4,324 |
| fatigue | 6,970 | 1.5 | 1.5 | 1,362 |
| headache | 5,048 | 1.4 | 1.3 | 551 |
| drug ineffective | 5,238 | 0.7 | 0.7 | 833 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.